Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23735937 | 0.82 | JAK3 (0.39) | JAK3SMN1; SMN2 | |
| SCHEMBL22185432 | 0.81 | JAK3 (0.39) | JAK3SMN1; SMN2HRH3SLC6A9 | |
| SCHEMBL20314877 | 0.81 | JAK3 (0.39) | JAK3SMN1; SMN2HRH3SLC6A9 | |
| SCHEMBL23569701 | 0.81 | JAK3 (0.39) | JAK3SMN1; SMN2HRH3SLC6A9 | |
| SCHEMBL22967829 | 0.75 | JAK3 (0.36) | JAK3SMN1; SMN2 | |
| SCHEMBL23308416 | 0.73 | HRH3 (0.39) | HRH3 | |
| SCHEMBL2033628 | 0.73 | — | — | |
| SCHEMBL23366022 | 0.73 | JAK3 (0.38) | JAK3SMN1; SMN2HRH3 | |
| SCHEMBL21610061 | 0.73 | JAK3 (0.36) | JAK3SMN1; SMN2 | |
| SCHEMBL24476768 | 0.73 | JAK3 (0.36) | JAK3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230011726-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011726-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | JAK3 2361/4885SMN1; SMN2 3852/4885HRH3 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.